内镜袖状胃成形术(ESG)治疗肥胖的前瞻性试验(EGO试验)
内镜下袖状胃成形术(ESG)治疗肥胖的前瞻性试验
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
研究概览
详细说明
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Armelle TAKEDA
- 电话号码:0033 390 413608
- 邮箱:armelle.takeda@ihu-strasbourg.eu
研究联系人备份
- 姓名:Clinical Research Team
- 邮箱:rc-ihu@ihu-strasbourg.eu
学习地点
-
-
-
Aix-en-Provence、法国
- 招聘中
- Hôpital Privé de Provence
-
接触:
- Hugues SEBBAG
- 电话号码:0033 4 42 21 12 11
- 邮箱:hsebbag.ppr@hotmail.fr
-
Besançon、法国
- 尚未招聘
- Polyclinique de Franche-Comté
-
接触:
- Henry-Alexis MERCOLI
- 电话号码:0033 3 81 41 81 41
- 邮箱:docteur.mercoli@gmail.com
-
Lille、法国
- 尚未招聘
- Hôpital HURIEZ
-
接触:
- Robert CAIAZZO
- 电话号码:0033 3 20 44 42 73
- 邮箱:robert.caiazzo@univ-lille2.fr
-
Lyon、法国
- 招聘中
- Clinique de la Sauvegarde
-
接触:
- Marie-Cécile BLANCHET
- 电话号码:+33 4 37 49 70 10
- 邮箱:blanchet@chirurgien-digestif.com
-
Lyon、法国
- 招聘中
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
接触:
- Maud ROBERT
- 电话号码:0033 4 72 11 62 61
- 邮箱:Maud.robert@chu-lyon.fr
-
Montpellier、法国
- 尚未招聘
- Clinique Clémentville
-
接触:
- Marta SILVESTRI
- 电话号码:0033 4 67 06 70 00
- 邮箱:docteur.m.silvestri@gmail.com
-
Saint-Etienne、法国
- 尚未招聘
- Centre Mutualiste de l'Obésité
-
接触:
- Pierre BLANC
- 电话号码:0033 4 77 81 82 88
- 邮箱:PBLANC@mutualite-loire.com
-
Saint-Grégoire、法国
- 尚未招聘
- CHP Saint-Grégoire
-
接触:
- Adrien STERKERS
- 电话号码:+33 2 99 23 93 10
- 邮箱:asterkers@vivalto-sante.com
-
Strasbourg、法国
- 招聘中
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
接触:
- Silvana PERRETTA
- 电话号码:0033 3 69 55 05 31
- 邮箱:perretta@unistra.fr
-
Sète、法国
- 招聘中
- Polyclinique Sainte Thérèse
-
接触:
- Thibaut COSTE
- 电话号码:0033 4 67 18 88 20
- 邮箱:thibautcoste@gmail.com
-
Échirolles、法国
- 尚未招聘
- Clnique des Cèdres
-
接触:
- Fabien STENARD
- 电话号码:0033 4 56 58 14 90
- 邮箱:fabien.stenard@cliniquedescedres.com
-
-
-
-
-
Baie-Mahault、瓜德罗普岛
- 尚未招聘
- Clinique les Eaux Claires
-
接触:
- Venetia AVENDANO
- 电话号码:0033 5 90 25 95 65
- 邮箱:zulemacu@yahoo.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult patients with obesity scheduled for endoscopic gastroplasty
描述
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
所有计划接受内镜胃成形术(ESG)的成年肥胖患者
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total Body Weight Loss
大体时间:At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Excess weight loss
大体时间:At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
大体时间:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
大体时间:From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
大体时间:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
大体时间:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
大体时间:From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
合作者和调查者
调查人员
- 首席研究员:Silvana PERRETTA, MD-PhD、Hôpitaux Universitaires de Strasbourg
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.